Sucampo Pharmaceuticals to Present at the CIBC World Markets 18th Annual Healthcare Conference

Sucampo Pharmaceuticals, Inc., (Nasdaq: SCMP) an emerging pharmaceutical company developing prostone-based therapies for age-related and other diseases, today announced that its senior management will present at the CIBC World Markets 18th Annual Healthcare Conference at the Waldorf-Astoria Hotel in New York City. The presentation will be webcast live over the internet beginning at 12:45 p.m. ET Monday, November 5.

A link to the live webcast will be available by logging on to the “For Investors” section of the Company’s website, www.sucampo.com, and clicking “Webcasts & Presentations.” A link to the archived version of the presentation also will be available on the Company’s website.

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc., an emerging pharmaceutical company based in Bethesda, MD, focuses on the development and commercialization of drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. The therapeutic potential of prostones was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals’ chairman and chief executive officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding chief executive officer and advisor, international business development. Sucampo Pharmaceuticals’ first product, AMITIZA® (lubiprostone), received marketing approval from the FDA in January 2006. To learn more about Sucampo Pharmaceuticals and its products, visit www.sucampo.com.